Education
About Us
Working with TipRanks
Follow Us
Compass Therapeutics (CMPX)
NASDAQ:CMPX
CMPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $4.08
Previous CloseN/A
Volume16.21M
Average Volume (3M)862.79K
Market Cap
$262.74M
Enterprise Value$79.75M
Total Cash (Recent Filing)$23.67M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
May 12, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding138,282,500
10 Day Avg. Volume891,188
30 Day Avg. Volume862,786
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)375.80
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-42.20
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$9.83Price Target Upside338.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Compass Therapeutics News
PremiumCompany Announcements
Compass Therapeutics Reports Positive Phase 2/3 Trial Results
PremiumCompany Announcements
Compass Therapeutics Reports 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressTovecimig has demonstrated promising early clinical data in combination with Paclitaxel in biliary tract cancer where there are currently limited treatment options.
Financial StabilityCMPX reported $127mn in cash and cash equivalents, which they expect to provide runway into the first quarter of 2027.
Market OpportunityTovecimig addresses a potential $1.4Bn US total addressable market in second-line biliary tract cancer and a potential $1.3Bn US total addressable market in DLL4+ metastatic colorectal cancer.
Bears Say
Clinical UncertaintiesThere are a number of clinical and regulatory uncertainties around the tovecimig program.
Competitive RisksPotential risks to the valuation include the emergence of new competitors, particularly in the PD-1 x VEGF space, and any potential R&D, regulatory, and commercial setbacks.
Trial ResultsThe success of the tovecimig trial is critical, especially because tovecimig failed to meet the pre-specified threshold to advance as a monotherapy in colorectal cancer.
---
Ownership Overview
18.56% Insiders
5.66% Mutual Funds
55.02% Other Institutional Investors
14.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPX FAQ
What was Compass Therapeutics’s price range in the past 12 months?
Compass Therapeutics lowest stock price was $0.77 and its highest was $4.08 in the past 12 months.
What is Compass Therapeutics’s market cap?
Compass Therapeutics’s market cap is $262.74M.
When is Compass Therapeutics’s upcoming earnings report date?
Compass Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 39 days.
How were Compass Therapeutics’s earnings last quarter?
Compass Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.098 by -$0.012.
Is Compass Therapeutics overvalued?
According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued.
Does Compass Therapeutics pay dividends?
Compass Therapeutics does not currently pay dividends.
What is Compass Therapeutics’s EPS estimate?
Compass Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Compass Therapeutics have?
Compass Therapeutics has 138,282,500 shares outstanding.
What happened to Compass Therapeutics’s price movement after its last earnings report?
Compass Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.098. Following the earnings report the stock price went down -1.684%.
Which hedge fund is a major shareholder of Compass Therapeutics?
Currently, no hedge funds are holding shares in CMPX
---
Compass Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.83 (338.84% Upside)
$9.83 (338.84% Upside)
Blogger Sentiment
Bullish
CMPX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.04%
12-Months-Change
Fundamentals
Return on Equity
-36.07%
Trailing 12-Months
Asset Growth
-10.50%
Trailing 12-Months
Company Description
Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
---
CMPX Stock 12 Month Forecast
Average Price Target
$9.83
▲(338.84% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Allogene Therapeutics
―
ADC Therapeutics
―
Best Analysts Covering CMPX
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+31.05%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +31.05% per trade.
---